First Time Loading...
A

Aquestive Therapeutics Inc
NASDAQ:AQST

Watchlist Manager
Aquestive Therapeutics Inc
NASDAQ:AQST
Watchlist
Price: 2.765 USD 0.55%
Updated: Jun 10, 2024

Aquestive Therapeutics Inc
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Aquestive Therapeutics Inc
Long-Term Debt Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Long-Term Debt Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
A
Aquestive Therapeutics Inc
NASDAQ:AQST
Long-Term Debt
$28.8m
CAGR 3-Years
-6%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Long-Term Debt
$25.1B
CAGR 3-Years
-6%
CAGR 5-Years
-2%
CAGR 10-Years
7%
Bristol-Myers Squibb Co
NYSE:BMY
Long-Term Debt
$49.5B
CAGR 3-Years
4%
CAGR 5-Years
54%
CAGR 10-Years
21%
Pfizer Inc
NYSE:PFE
Long-Term Debt
$61.3B
CAGR 3-Years
20%
CAGR 5-Years
11%
CAGR 10-Years
8%
Merck & Co Inc
NYSE:MRK
Long-Term Debt
$31.1B
CAGR 3-Years
9%
CAGR 5-Years
7%
CAGR 10-Years
5%
Eli Lilly and Co
NYSE:LLY
Long-Term Debt
$24.6B
CAGR 3-Years
15%
CAGR 5-Years
13%
CAGR 10-Years
17%

See Also

What is Aquestive Therapeutics Inc's Long-Term Debt?
Long-Term Debt
28.8m USD

Based on the financial report for Mar 31, 2024, Aquestive Therapeutics Inc's Long-Term Debt amounts to 28.8m USD.

What is Aquestive Therapeutics Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
-7%

Over the last year, the Long-Term Debt growth was 14%. The average annual Long-Term Debt growth rates for Aquestive Therapeutics Inc have been -6% over the past three years , -7% over the past five years .